Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004

Sturm, Andreas; Atreya, Raja; Bettenworth, Dominik; Bokemeyer, Bernd; Dignaß, Axel; Ehehalt, Robert; Germer, Christoph T.; Grunert, Philip; Helwig, Ulf; Herrlinger, Klaus; Kienle, Peter; Kreis, Martin E.; Kucharzik, Torsten; Langhorst, Jost; Ockenga, Johann; Ott, Claudia; Siegmund, Britta; Zeißig, Sebastian; Stallmach, Andreas

doi:10.1055/a-1713-3941

Cited by 67 publications

(52 citation statements)

References 856 publications

(1,217 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, in an attempt to include the plants possibly used by patients, which do not appear in the scarce survey data, additional sources were used. That includes HMPC-monographs, treatment guidelines [23][24][25], and database searches (PubMed and Web of Science, search terms: herbal medicine, herbal supplement, rheumatoid arthritis, osteoarthritis, and chronic inflammatory bowel disease).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Herb–Drug Interaction in Inflammatory Diseases: Review of Phytomedicine and Herbal Supplements

Lippert

Renner

2022

JCM

View full text Add to dashboard Cite

Many people worldwide use plant preparations for medicinal purposes. Even in industrialized regions, such as Europe, where conventional therapies are accessible for the majority of patients, there is a growing interest in and usage of phytomedicine. Plant preparations are not only used as alternative treatment, but also combined with conventional drugs. These combinations deserve careful contemplation, as the complex mixtures of bioactive substances in plants show a potential for interactions. Induction of CYP enzymes and pGP by St John’s wort may be the most famous example, but there is much more to consider. In this review, we shed light on what is known about the interactions between botanicals and drugs, in order to make practitioners aware of potential drug-related problems. The main focus of the article is the treatment of inflammatory diseases, accompanied by plant preparations used in Europe. Several of the drugs we discuss here, as basal medication in chronic inflammatory diseases (e.g., methotrexate, janus kinase inhibitors), are also used as oral tumor therapeutics.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Common drugs for the treatment of rheumatoid arthritis, IBD and osteoarthritis were taken from surveys [30,36] and treatment guidelines [23][24][25][47][48][49]. Table 2 shows the drugs considered with their indications and interaction potential.…”

Section: Potential Herb-drug Interactionsmentioning

confidence: 99%

Herb–Drug Interaction in Inflammatory Diseases: Review of Phytomedicine and Herbal Supplements

Lippert

Renner

2022

JCM

View full text Add to dashboard Cite

show abstract

“…The global prevalence of inflammatory bowel disease has steadily increased within the last two decades, with an average of 1 in 200 people affected (Ng et al, 2017 ). Crohn's disease (CD) has an overall incidence in Germany of 6.6 new cases per 100,000 inhabitants per year, with ~25,500 patients per year who require inpatient treatment (Preiß et al, 2014 ; Ng et al, 2017 ; Sturm et al, 2022 ). Due to a large number of symptoms, the health-related quality of life (HRQOL) of many patients with CD is comprehensibly impaired in the most productive years of their lives.…”

Section: Introductionmentioning

confidence: 99%

Mind-body-medicine and comprehensive lifestyle-modification in patients with Crohn's disease—Feasibility of a randomized controlled trial under pandemic circumstances

Bauer

Löffler

Öznur

et al. 2022

Front. Integr. Neurosci.

Self Cite

View full text Add to dashboard Cite

IntroductionMind-body medicine (MBM) focuses on stress reduction and lifestyle changes. The primary objective of this pilot trial was to test study feasibility of a complex integrative MBM program for patients with Crohn's disease (CD), especially in rural regions, and under pandemic conditions.MethodsPatients were stratified and randomized to the intervention group (IG) or the control group (CG). The intervention included a weekly 6-h session for 10 weeks. The CG (waiting list) received an initial 90-min workshop and started the intervention 9 months later. The primary outcome for study feasibility was recruitment and retention rates, as well as reasons for drop-out. The trial took place in Bamberg, Germany (September 2020 to December 2021).ResultsTotally 700 members of the German Crohn's and Colitis Organization—DCCV—were contacted. A total of 15% (102/700; 95% CI 12–17%) expressed interest to participate. Following screening, 41% (95% CI 32–50) were randomized to IG (n = 22) and CG (n = 20). The patients were on average (±standard deviation) 48 ± 13 years old, 67% were female, and have been suffering from CD for 20 ± 12 years. Patients traveled 71.5 ± 48.7 km (range: 9–227 km) to the intervention with no differences between IG and CG. At the 6-month follow-up, 36/42 (86%, 95% CI 74–95%) participants completed final assessment and 19/22 (86%, 95% CI 70–100%) the intervention. The most important reasons for non-responding were work-related (12/60; 20%) and for or drop-out pandemic-related anxiety (3/6). No patient and staff member became infected with SARS-CoV-2 during the study.ConclusionThe feasibility of the MBM study was confirmed in terms of predefined recruitment and retention criteria, both despite difficult conditions (including the rural setting) and patients' fears associated with the pandemic. It was crucial to develop appropriate hygiene and safety concepts that enable chronically ill patients to participate in helpful group-based interventions even under pandemic conditions.Clinical trial registrationClinicalTrials.gov, identifier: NCT05182645.

show abstract

“…Ein weiterer Vorteil der Darmsonografie stellt die Erfassung der transmuralen Krankheitsaktivität dar, die in den letzten Jahren zunehmend in den Fokus der Diagnostik gerückt ist und immer häufiger als Zielkriterium für antientzündliche Therapien diskutiert wird [4]. In der jüngsten ECCO/ ESGAR-Leitlinie wurde ebenso wie in den Morbus Crohn-und Colitis ulcerosa-Leitlinien der Deutschen Gesellschaft für Verdauungs-und Stoffwechselerkrankungen (DGVS) der Stellenwert des Darmultraschalls bei CED für die genannten Indikationsbereiche klar definiert [5,6,7]. Auch die aktuellen STRIDE-2-Kriterien empfehlen den Einsatz des Darmultraschalls zur Evaluation der Entzündungsaktivität und beschreiben die transmurale Heilung als Kriterium, welches mit einer günstigen Prognose assoziiert ist [8].…”

Section: Introductionunclassified

Positionspapier zur Befunderhebung von Darmultraschallbefunden bei chronisch entzündlichen Darmerkrankungen

et al. 2022

Self Cite

View full text Add to dashboard Cite

Zusammenfassung Hintergrund Zur Diagnosestellung, Erkennung von Erkrankungskomplikationen sowie zur Verlaufskontrolle bei Patienten mit Morbus Crohn und Colitis ulcerosa wird zunehmend der Darmultraschall eingesetzt. Eine systematische Befunderhebung und Dokumentation sind wichtig, um die Qualität der Befunderstellung und die Kommunikation zwischen den Fachgruppen zu verbessern. Das vorliegende Positionspapier beschreibt die Voraussetzungen für eine optimale Befunderhebung des Darmultraschalls bei Patienten mit chronisch-entzündlichen Darmerkrankungen (CED). Methoden Eine Experten-Konsensusgruppe bestehend aus Gastroenterologen, Radiologen, Pathologen, Kinder- und Jugend-Gastroenterologen und Chirurgen führte eine systematische Literaturrecherche durch. In einem Delphi-Verfahren wurde unter Mitgliedern des Kompetenznetzes Darmerkrankungen und der Deutschen Röntgengesellschaft (DRG) über relevante Kriterien bei der Befunderhebung von Darmultraschallbefunden abgestimmt. Die daraus resultierenden Statements wurden in einer Experten-Konsensusgruppe verabschiedet. Ergebnis Praxisorientierte Empfehlungen für eine optimale Befunderhebung mit einer standardisierten Terminologie wurden entwickelt. Der Fokus der Erhebung lag auf der Beschreibung der Entzündungsaktivität sowie der Komplikationen bei CED. Minimale Anforderungen für eine standardisierte Befunderhebung wurden definiert. Zusammenfassung Das vorliegende Manuskript bietet praktische Empfehlungen zur Optimierung und Vereinheitlichung der Befunderhebung bei Darmultraschall-Untersuchungen bei CED.

show abstract

Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004

Cited by 67 publications

References 856 publications

Herb–Drug Interaction in Inflammatory Diseases: Review of Phytomedicine and Herbal Supplements

Herb–Drug Interaction in Inflammatory Diseases: Review of Phytomedicine and Herbal Supplements

Mind-body-medicine and comprehensive lifestyle-modification in patients with Crohn's disease—Feasibility of a randomized controlled trial under pandemic circumstances

Positionspapier zur Befunderhebung von Darmultraschallbefunden bei chronisch entzündlichen Darmerkrankungen

Contact Info

Product

Resources

About